Advertisement

Evidence for frequent reactivation of the Oka varicella vaccine strain in healthy vaccinees

  • P. R. Krause
Conference paper

Summary

Serum antibody levels and infection rates were followed for 4 years in 4,631 children immunized with the recently licensed Oka strain varicella vaccine. Anti-VZV titers declined over time in high-responder subjects, but rose in vaccinees with low titers. Among subjects with low anti-VZV titers, the frequency of clinical sequelae and immunological boosting significantly exceeded the 13%/yr rate of exposure to wild type varicella. These findings indicate that the Oka strain of VZV persisted in vivo, and reactivated as serum antibody titers declined after vaccination. This mechanism may improve vaccine-associated long-term immunity.

Keywords

Antibody Titer Herpes Zoster Varicella Vaccine Chickenpox Infection Combine Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arvin A, Koropchak C, Wittek A (1983) Immunologic evidence of re-infection with varicella-zoster virus. J Infect Dis 148: 200–205PubMedCrossRefGoogle Scholar
  2. 2.
    Asano Y, Suga S, Yoshikawa T, Kobayashi I, Tazaki T, Shibata M, Tsuzuki K, Ito S (1994) Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94: 524–526PubMedGoogle Scholar
  3. 3.
    Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, Chartrand SA, Cho I, Ngai A, White CJ (1993) Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 92: 833–837PubMedGoogle Scholar
  4. 4.
    Brunell PA, Argaw T (2000) Chickenpox due to vaccine virus contracted from a vaccinee with zoster. Pediatrics 106: E28PubMedCrossRefGoogle Scholar
  5. 5.
    Brunell PA, Taylor J, Geiser CF, Frierson L, Lydick E (1986) Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77: 53–65PubMedGoogle Scholar
  6. 6.
    Choo PW, Donahue JG, Manson JE, Platt R (1995) The epidemiology of varicella and its complications. J Infect Dis 172: 706–712PubMedCrossRefGoogle Scholar
  7. 7.
    Cohen JI, Brunell PA, Straus SE, Krause PR (1999) NIH conference: recent advances in varicella-zoster virus infection. Ann Intern Med 130: 922–932PubMedGoogle Scholar
  8. 8.
    Colton T (1974) Statistics in medicine. Little, Brown & Co., BostonGoogle Scholar
  9. 9.
    Finger R, Hughes J, Meade B, Pelletier A, Palmer C (1994) Age-specific incidence of chickenpox. Pub Health Rep 109: 750–755Google Scholar
  10. 10.
    Hardy I, Gershon AA, Steinberg SP, LaRussa P (1991) The incidence of zoster after immunization with live attenuated varicella vaccine. N Engl J Med 325: 1545–1550PubMedCrossRefGoogle Scholar
  11. 11.
    Hope-Simpson RE (1965) The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc London 58: 9–20Google Scholar
  12. 12.
    Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML (1997) A long-term prospective study of varicella vaccine in healthy children. Pediatric 100: 761–766CrossRefGoogle Scholar
  13. 13.
    Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW (1986) Purification of individual varicella-zoster virus (VZV) glycoproteins gpl, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 14: 177–188PubMedCrossRefGoogle Scholar
  14. 14.
    Krause PR, Klinman DM (1995) Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatrics 127: 518–525CrossRefGoogle Scholar
  15. 15.
    Krause PR, Klinman DM (2000) Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nature Med 6: 451–454PubMedCrossRefGoogle Scholar
  16. 16.
    Kuter B, Weibel R, Guess H, Mattthews H, Morton D, Neff B, Provost P, Watson B, Starr S, Plotkin S (1991) Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9: 643–647PubMedCrossRefGoogle Scholar
  17. 17.
    Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist V, Wahren B (1986) Clinical and subclinical reactivation of varicella-zoster virus in immunocompromised patients. J Infect Dis 153: 840–847PubMedCrossRefGoogle Scholar
  18. 18.
    Luby J, Ramirez-Ronda C, Rinner S, Hull A, Vergne-Marini P (1977) A longitudinal study of varicella-zoster virus infections in renal transplant recipients. J Infect Dis 135: 659–663PubMedCrossRefGoogle Scholar
  19. 19.
    Merck & Co. (1998) Varivax [varicella virus vaccine live (Oka/Merck)] package circular In: 52nd Physician’s desk reference. Medical Economics Co., Montvale, pp 1762–1765Google Scholar
  20. 20.
    Plotkin SA (1994) Vaccines for varicella-zoster virus and cytomegalovirus: Recent progress. Science 265: 1383–1385PubMedCrossRefGoogle Scholar
  21. 21.
    Scheiermann N, Gesemann M (1993) Anti-HBs antibody kinetics — A 4 year follow-up after hepatitis B vaccination. Zbl Bakt 278: 120–126Google Scholar
  22. 22.
    Straus SE, Reinhold W, Smith HA, Ruyechan WT, Henderson DK, Blaese RM, Hay J (1984) Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med 311: 1362–1364PubMedCrossRefGoogle Scholar
  23. 23.
    Tomita H, Tanaka M, Kukimoto N, Ikeda M (1988) An ELISA study on varicella-zoster virus infection in acute peripheral facial palsy. Acta Otolaryngol (Stockh) [Suppl] 446: 10–16Google Scholar
  24. 24.
    Varis T, Vesikari T (1996) Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis [Suppl 3] 174: S330–334CrossRefGoogle Scholar
  25. 25.
    Wasmuth EH, Miller WJ (1990) Sensitive ELISA for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 32: 189–193PubMedCrossRefGoogle Scholar
  26. 26.
    Watson BA, Starr SE (1994) Commentary: varicella vaccine for healthy children. Lancet 343: 928–929PubMedCrossRefGoogle Scholar
  27. 27.
    Weibel RE, J NB, Kuter BJ (1984) Live attenuated varicella vaccine: efficacy trial in healthy children. N Engl J Med 310: 1409–1415PubMedCrossRefGoogle Scholar
  28. 28.
    Wharton M (1996) The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 10: 571–581PubMedCrossRefGoogle Scholar
  29. 29.
    Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM (1992) Subclinical varicellazoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165: 119–126PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2001

Authors and Affiliations

  • P. R. Krause
    • 1
    • 2
  1. 1.Laboratory of DNA VirusesDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, CBER/FDABethesdaUSA
  2. 2.Division of Viral Products, CBER/FDABethesdaUSA

Personalised recommendations